Atai Beckley N.V. (ATAI) is a Buy on Mental Therapeutics Opportunities [Yahoo! Finance]
AtaiBeckley Inc. (ATAI)
US:NASDAQ Investor Relations:
ir.atai.net.cn
Company Research
Source: Yahoo! Finance
N.V. (NASDAQ:ATAI) with a Buy rating and a $16 price target. According to the research firm, the company boasts of differentiated opportunities owing to its pipeline of psychedelic and empathogenic drugs targeting considerable neuropsychiatric indications. Jones Trading expects Atai Beckley to benefit from emerging trends favoring the development of drugs in different classes. For starters, the company is well-positioned to benefit from its lead assets, BPL-003 and VLS-01, for the treatment of resistant depression (TRD). Additionally, the research firm is buoyed by the TRD market, which is large enough and has sufficient unmet need to accommodate multiple treatments. The positive stance comes on the heels of the company developing its pipeline backed by a strengthened balance sheet, following the raising of $300 million. It has also advanced multiple clinical programs into late-stage development. The company has also deepened its position in next-generation mental health therapeut
Show less
Read more
Impact Snapshot
Event Time:
ATAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATAI alerts
High impacting AtaiBeckley Inc. news events
Weekly update
A roundup of the hottest topics
ATAI
News
- AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish [Seeking Alpha]Seeking Alpha
- BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 InitiationGlobeNewswire
- BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor DayGlobeNewswire
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA DecisionsPR Newswire
- AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 [Yahoo! Finance]Yahoo! Finance
ATAI
Earnings
- 11/12/25 - Miss
ATAI
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 3
- 2/26/26 - Form 144
- ATAI's page on the SEC website